Innovent Biologics

Innovent's 2025 reporting says the company kept pushing an intelligent upgrade of its R&D system, and sped up the deep integration of artificial intelligence technologies across the whole drug development chain.

Innovent's 2025 ESG report describes an AI+NGS wet-dry closed-loop antibody discovery platform that has been applied to multiple internal projects, shortening the antibody screening cycle and improving the efficiency of discovering high-quality candidate molecules.

Innovent says it has developed an AI-driven de novo design closed-loop system dedicated to small protein drug development. The same report says the system enables intelligent iteration from target elucidation to molecular optimization and has demonstrated a magnitude-level improvement in hit rates and R&D iteration speed in internal projects.

During the reporting period, Innovent upgraded its learning platform, turning the original online training platform into iTalent, an AI-powered intelligent learning platform.

Innovent's 2025 ESG report says protective measures implemented in 2024 for the WeMol computing platform and AI intelligence repository were followed by a security baseline for the electronic lab notebook system covering the R&D computing environment.